Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NRP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NRP2 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View NRP2 Products |
| Gene Delivery | NRP2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for preserving native conformation in cell-based assays. |
View NRP2 Products |
| Benchmark Ab | Anti-NRP2 Recombinant Antibody Recombinant positive control based on clinical candidate sequences. Sequence Verified. |
View NRP2 Products |
| Validator | NRP2 siRNA Set For knockdown verification in target-specificity assays. |
View NRP2 Products |
| Related Target A | NRP1 Highly homologous family member. Crucial for off-target counter-screening to avoid systemic toxicity. |
View NRP1 Products |
| Related Target B | VEGF-C Primary functional ligand of NRP2. Essential for ligand-blocking and functional inhibition assays. |
View VEGFC Products |
| Related Target C | SEMA3F Class 3 Semaphorin ligand involved in NRP2-mediated axonal guidance and tumor metastasis signaling. |
View SEMA3F Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NRP1 Homology Cross-Reactivity | High-purity human NRP1 and NRP2 recombinant proteins available for parallel SPR/BLI counter-screening. |
| Native Conformation for Cell Assays | Lentiviral vectors for stable cell line generation, avoiding artificial VLP-associated artifacts. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live NRP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NRP2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and multi-specific immune cell engagers. As first-generation therapies reach the clinic, the next wave of R&D is targeting the tumor microenvironment (TME), where NRP2 plays a pivotal role in modulating immunosuppressive myeloid cells and driving therapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | aRrett Biomedical, Academic Institutions | Solid Tumors, Lymphatic Metastasis | Ligand-blocking assays (Need high-purity ECD-Fc proteins for VEGF-C/NRP2 interaction screening) |
| Antibody-Drug Conjugate (ADC) | Biotech Startups | Triple-Negative Breast Cancer, Prostate Cancer | Internalization Assay (Need sequence-verified antigens and stable cell lines for kinetic profiling) |
| Bispecific / Multi-specific | Global Biopharma Partners | Immunotherapy-resistant tumors | Dual-targeting validation (Need cross-reactive homologous panels including NRP1 and NRP2) |